ADX-629 Therapy for Sjogren-Larsson Syndrome

Inclusion Criteria: * Patricipant or participant's guardian is willing to provide written informed consent prior to the initiation of any study procedures. Assent will be solicited from participant intellectually capable of providing assent. * Participant is willing to comply with all study procedures and availability for the duration of the study. * Participant is 5-50 years of age at the time of enrollment. * Participant has a genetically-confirmed diagnosis of SLS with two pathogenic sequence variants in ALDH3A2. * Participant has active ichthyosis and neurologic symptoms of spasticity. * Participant is able to swallow oral tablet medication and is willing to adhere to the study regimen. * Participant is willing to suspend use of all topical creams 7 days before initial baseline evaluation and before the 12-week center visit. * Participant has not been treated with any experimental drug for 1 month before baseline visit and during ADX-629 treatment. * Participant who is sexually active agrees to use adequate contraception throughout the duration of the study, as follows: * For females of child-bearing potential: Negative pregnancy test at Baseline and compliant with a medically approved contraceptive regimen during the study or documented to be surgically sterile or postmenopausal. * For sexually-active men: Compliant with a barrier contraceptive regimen during the study. Exclusion Criteria: * History of any malignancy within 5 years of screening except for basal cell o…